We prospectively evaluated patients with completely resected uterine serous carcinoma (USC) treated with radiation ''sandwiched'' between carboplatin/paclitaxel (C/T). The primary objective was to determine the safety profile, and the secondary outcome was to evaluate progression-free and overall survival. Methods: Surgically staged patients with completely resected USC were enrolled to receive 3 cycles of paclitaxel 175 mg/m 2 and carboplatin (area under the curve, 6Y7.5) every 21 days, followed by radiotherapy and an additional 3 cycles of T/C at area under the curve of 5Y6 (6 cycles + radiotherapy). Toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 4.03. Kaplan-Meier and log-rank tests were used to compare survival probabilities. Results: One hundred forty patients were enrolled, of which 132 were evaluable, completed at least 3 cycles of chemotherapy and radiation. One hundred seven (81%) completed 6 cycles of chemotherapy and radiation. Patients with early-stage (I/II) disease have survival probabilities of 0.96 and 0.81 at 2 and 5 years. Patients with stage I USC and lymphovascular invasion have considerably worse overall survival, with 2.7 times' higher risk of death than those without lymphovascular invasion. Patients with late-stage (III/IV) disease had overall survival probabilities of 0.64 and 0.18 at 2 and 5 years, which is far higher survival than what has been reported in single-modality trials. Interestingly, and different than what is reported in other studies, there is no difference in survival in African Americans versus whites/other races who were evaluable. Of the 779 cycles administered, 22% and 14% of cycles were associated with ORIGINAL STUDY
U terine serous carcinoma (USC) is the most common nonendometrioid subtype of endometrial cancer, accounting for approximately 10% of all endometrial cancer cases. Usually diagnosed at an advanced stage, USC is an aggressive histologic subtype associated with a disproportionate number (39%) of endometrial cancer deaths. 1 The Cancer Genome Atlas molecular characterization data indicate that tumors in the ''serous-like'' cluster had significantly worse progression-free survival (PFS) than endometrioid histology. Recurrence of USC is common, occurring in up to 50% of patients with early disease and higher in patients with advanced disease. 2 The optimal adjuvant treatment following surgery for USC remains controversial. Studies have evaluated the role multimodal therapy, combining pelvic radiation therapy (RT) for local control with chemotherapy (CT) for systemic control. Studies have shown that sequential use of CT followed by pelvic RT in patients with stage III/IV endometrial cancer was associated with few pelvic recurrences, improved survival, and an acceptable toxicity profile.
3Y6
In a multi-institutional retrospective analysis of 356 patients with stages III/IV endometrial cancer (90% without measurable disease), including 86 patients with USC, Secord et al 7 compared outcomes in patients who received RTalone, CTalone, or various regimens of combined CT + RT. Chemotherapy + RT was associated with the best survival outcomes when compared with either CT or RT alone with acceptable toxicity. 7 A second multi-institutional retrospective analysis of 265 patients with optimally resected stage IIIC endometrial cancer demonstrated that adjuvant treatment with either RT alone or CT + RT was associated with improved survival outcomes compared with those who received CT only. 8 The same group subsequently evaluated the sequence of multimodal adjuvant therapy in 109 patients with advanced endometrial cancer and found a PFS and overall survival (OS) advantage for patients who received chemoradiation in ''sandwich'' fashion compared with patients who received CT followed by radiation or radiation followed by CT. 9 Importantly, there was no difference in toxicity, dose modifications, and dose reductions between the 3 groups. These studies are limited by the inclusion of multiple histologic subtypes. 9 Our group previously reported the safety, tolerability, and 3-year survival data of a ''nonrandomized'' phase 2 trial of adjuvant pelvic radiation ''sandwiched'' between paclitaxel and carboplatin in 81 women with completely resected USC. 10 The ''sandwich'' strategy hypothetically allows for control of systemic disease with CTwhile treating pelvic micrometastasis with RT. The sequential delivery of CTand RT limits the overall toxicity and allows for maximum therapeutic dosing for CT and RT. Treatment was well tolerated with grades 3 and 4 nonhematologic toxicity, dose reduction, and dose delay in 2.5%, 6%, and 8.5% of patients, respectively. 10 Based on promising survival data, this treatment became an institutional standard, and we continued to treat patients with this regimen. We present the combined tolerability and efficacy data for patients treated with ''sandwich'' therapy during and following the study protocol, allowing for extended 5-year follow-up after completion of adjuvant ''sandwich'' therapy.
METHODS
After institutional review board approval and clinical trials registration, eligible patients were initially recruited from 1999 to 2009 at Montefiore Medical Center/Albert Einstein College of Medicine to our previously reported phase 2 trial (Clinicaltrials.gov identifier: NCT00231868). 10 Eligible patients underwent surgical staging for histologically confirmed stage IYIV USC, which included hysterectomy, bilateral salpingooophorectomy, pelvic and para-aortic lymph node sampling, and peritoneal washings. Infracolic omentectomy was preferred but not required in patients without visible omental disease. Inclusion criteria included women who had at least 6 months of follow-up. Patients who died within the first 6 months of surgery were included in the analysis. Patients with grossly visible residual disease following surgery were excluded. In addition to following survival end points in subjects enrolled on the original ''nonrandomized'' phase 2 protocol, patients who received the same therapy but treated ''off protocol'' were included in this analysis. The treatment and toxicity data for patients who received treatment on and off protocol were followed until 2015. Surgical criteria remained the same for patients recruited off protocol, including lymph node sampling without application of sentinel lymph node biopsy. The institutional review board approval was expanded to include the retrospective review of all patients who received this treatment off protocol until 2015.
Chemotherapy
Postoperatively, all patients received adjuvant platinum/ taxane CT and radiation in ''sandwich'' fashion. Paclitaxel was administered at a dose of 175 mg/m 2 over 3 hours. Carboplatin was administered at area under the curve (AUC) 6 to 7.5 for cycles 1 to 3 and AUC 5 to 6 for cycles 4 to 6. In the original pilot phase of this study, we optimized the carboplatin dosing, specifically due to hematologic toxicity often seen after RTwith the higher carboplatin doses. 11 Optimization led to our standard carboplatin dose of AUC 6 before RT and AUC 5 after RT, for the subsequent phase 2 trial. Chemotherapy was administered every 21 days for 3 cycles prior to proceeding with pelvic RT. Following completion of RT, patients received an additional 3 cycles of platinum/taxane CT at 21-day intervals, for a total of 6 CT cycles. Cycle 4 of CTwas initiated within 1 to 2 weeks of completion of the external beam radiotherapy (EBRT) (overlapping with brachytherapy). Standard paclitaxel and carboplatin premedications were administered to minimize hypersensitivity and nausea. Treatment modifications for hematologic toxicities included cycle delay until recovery with subsequent dose reduction. Cycle delays were defined as delay in CT 1 week or more. Granulocyte colony-stimulating factor (G-CSF) was administered based on provider preference.
Radiation Therapy
Radiation therapy began 1 week after the third cycle of CT. Patients received a total of 45 Gy of pelvic EBRT. Patients received a daily fraction of 1.8 Gy, 5 days per week for a total of 5 weeks. A 4-field conformal RT (anterior-posteriorposterior-anterior opposed and lateral opposed fields) or intensitymodulated RT (IMRT) technique was used with equal to or greater than 6-MV beam. Once IMRT was introduced at our institution in 2005, all patients prescribed EBRT received IMRT. The fields were extended to include the para-aortic nodal region in the case of 2 or more positive pelvic nodes or documented positive para-aortic lymph nodes. In addition to EBRT, most patients received high-dose-rate brachytherapy via vaginal cylinder to boost the dose to the proximal one-half to two-thirds of the vagina. Segmented cylinders of the largest size accommodated by the vagina were used. Three fractions of 5 Gy each prescribed to 0.5-cm depth from the vaginal surface were given once weekly using the Nucletron microSelectron highdose-rate 192 Ir remote after-loading technique. Adverse events were monitored for each cycle during therapy and graded with attributions using the National Cancer Institute Common Toxicity Criteria, version 4.03.
Statistical Methods
The distribution of continuous variable was numerically summarized using mean and SD, whereas nonnormal data were presented with median and range. The categorical variables were presented as frequency and percentage. The probability of survival was examined using Kaplan-Meier survival procedure and log-rank test to assess the association between exploratory variables and outcomes: PFS and OS. Cox regression was used to analyze the risk factors for PFS and OS. Proportional hazards assumption was checked, and variables that were significant at 20% at univariate level along with a priori confounding variables such as age, race, and body mass index were considered for multivariable models. All analyses were performed using SAS version 9.4.
RESULTS
A total of 140 patients were prescribed ''sandwich'' therapy on (n = 48) and off (n = 92) protocol; 132 women were evaluable, defined as having completed at least 3 cycles of CT and RT (Fig. 1) . The distribution of the patient characteristics is presented in Table 1 . This is an ethnically and racially diverse population.
At diagnosis, 74.3% had stage I or II disease, and 25.7% had completely resected stage III or IV disease. The patients were followed up for a median of 46.7 months (range, 2.1Y179.4 months). Over the 15-year evaluation period, 33% (n = 46) of the cohort died, 34 patients died of disease, and 12 patients died of other causes. Of the patients who had treatment, 107 (76%) had completed the protocol-specified treatment, 25 (17.8%) had received at least 3 cycles of CT followed by RT, and 8 (5.7) completed fewer than 3 cycles of CT or had incomplete RT. Thus, a total of 132 patients who completed at least 3 cycles of CT followed by RT were considered evaluable for all time-to-event analysis. Of those (n = 8) who were excluded from the analysis and did not complete at least 3 cycles of CT followed by RT, 38% (n = 3) died of disease. Of the 132 patients who completed at least 3 cycles of CT followed by RT, 116 patients were prescribed EBRT and brachytherapy, 9 patients were prescribed EBRT alone, and 7 patients were prescribed brachytherapy alone. One hundred seven (76.4%) of 140 patients completed the full prescribed treatmentV6 cycles of CT and RT; 94 patients received 6 cycles of CT, EBRT, and brachytherapy; and 13 patients had 6 cycles of CT followed by EBRT or brachytherapy. FIGURE 1. CONSORT diagram of patients receiving ''sandwich'' therapy. Of the 140 subjects receiving ''sandwich'' therapy, 48 were treated on protocol, and 92 were treated with the same regimen but not on protocol. Survival analysis was performed in all patients who received at least 3 cycles of CT followed by RT (n = 132). Toxicity analysis was performed on all cycles administered (n = 779). Of the 107 patients receiving the fully prescribed therapy, 13 patients received 6 cycles and EBRT or brachytherapy, and 94 patients received 6 cycles, EBRT, and brachytherapy.
Time-to-Event Outcomes
Survival analyses was considered only in those patients who completed at least 3 cycles of CT and RT (n = 132). Progression-free survival results were similar to OS; therefore, only OS is reported here. 
Progression-Free Survival

Overall Survival
The probabilities of OS among study participants at 1, 2, and 5 years are 0.97, 0.89, and 0.68, respectively (Fig. 2) In the multivariable model, no difference in PFS and OS was observed between African Americans versus whites and other races. Interestingly, there is a trend toward higher risk of disease progression in Hispanics compared with white patients (hazard ratio [HR], 2.7), approaching statistical significance, P = 0.07 (Table 2) .
We further performed a subgroup analysis of patients with stage I disease (n = 92) evaluating the effect of the presence of LVSI on OS (Fig. 3) . Of the stage I patients, 27.2% (25/92) had LVSI, and 6.6% (6/92) were indeterminate and were excluded in the analysis. The probabilities of OS at 1, 2, and 5 years among those patients with LVSI and no LVSI were 0.96, 0.94, and 0.78 and 0.98, 0.96, and 0.89, respectively, which was statistically significant (P = 0.03) (Fig. 3) . Patients with stage I disease and LVSI had a 2.7 times' higher risk of death (HR, 2.7; 95%CI, 1.02Y6.91; P = 0.04) compared with patients without LVSI. Toxicity Table 3 describes observed hematologic and nonhematologic toxicities. A total of 779 cycles of CTwere administered, and grades 3 and 4 toxicities were tabulated. Of the 779 cycles administered, 22% and 14% of cycles were associated with grades 3 and 4 hematologic toxicities, respectively. More neutropenia occurred in cycles 1 to 3, and more thrombocytopenia occurred in cycles 4 to 6 (Table S1, Supplemental Digital Content 1, http:// links.lww.com/IGC/A837). There was 1 CT-related death after cycle 2 of CT in an 82-year-old patient with stage IIIC2 disease who suffered grade 4 neutropenia, grade 3 anemia, and grade 4 thrombocytopenia. This patient developed Klebsiella urosepsis and died of sepsis after receiving cycle 2 of CT. Furthermore, grades 3 and 4 nonhematologic toxicities occurred in 6.9% of cycles, including infectious (n = 14), neurologic (n = 7), deep vein thrombosis/pulmonary embolus (n = 7), metabolic disturbances (n = 13), and gastrointestinal (n = 5). Overall, 33 (61.1%) of 54 dose reductions and 51 (62.9%) of all 81 CT delays occurred after RT.
Of note, 57 patients (40.7%) required no G-CSF support, whereas 81 patients (57.9%) received G-CSF support. Of the 81 patients who received G-CSF support, 3 patients (2.1%) received it with all 6 CT cycles, 40 (28.6%) initiated it prior to RT with cycle 2 or 3, 13 (9.3%) received it immediately after RT starting with cycle 4, and 11 (7.9%) with cycle 5 or 6. Fourteen additional patients received G-CSF support with 1 to 2 random but nonconsecutive cycles. Of note, 56 patients (40%) received G-CSF support by cycle 4 of CT.
DISCUSSION
We report the largest prospective phase 2 single-institution clinical trial investigating the role of radiation ''sandwiched'' between CT in the management of patients with optimally resected USC. The long-term follow-up demonstrates that ''sandwich'' therapy is a feasible, well-tolerated treatment approach with acceptable toxicities and high efficacy compared with the literature data of single modalities of RT or CT alone. The survival probability in stage I/II patients was 96% at 2 years and 81% at 5 years, supporting the treatment of patients with early-stage disease, especially the higher-risk patients with LVSI. We demonstrate high survival rates even in stage III patients, with OS probabilities of 74% at 2 years and 44% at 5 years. As expected, the majority of the CT delays and dose reductions occurred after the RT. However, these numbers were slightly improved when compared with our prior reports likely secondary to increased G-CSF use.
In our follow-up period, we noticed a significant relationship of early-stage USC with LVSI. Whereas PFS was unaffected, patients with stage I USC and LVSI had considerably worse OS, with a 2.7 times' higher risk of death. This is consistent with recent literature suggesting that LVSI is an important predictor of advanced disease and an independent prognostic factor associated with worse OS. 12Y14 The presence of LVSI in early-stage disease may further change the management recommendations for adjuvant RT in patients who would previously have been recommended vaginal brachytherapy alone. Recent pooled analysis of PORTEC 1 and 2 trials aimed to quantify LVSI and correlate this to risk and type of recurrence in patients with endometrioid endometrial cancer of all grades. 15 This trial concluded that ''substantial'' LVSI, in contrast to focal or no LVSI, was the strongest independent risk factor for pelvic recurrence, and the authors recommended treatment with EBRT in patients with stage I, high-grade, endometrioid cancer with ''substantial'' LVSI. 15 To our knowledge, this is the first prospective report evaluating the prognostic effect of LVSI on OS in patients with USC.
Recently, 2 phase 3 trials were initiated to investigate the role of multimodal therapy using CT and RT compared with single-modality alone. PORTEC 3 investigated the benefit of adjuvant CT during and after RT compared with RT alone in women with high-risk endometrial cancer, 16% of which had serous histology. 16 Serous histology was defined as having at least a 25% serous component. 16 Data indicated that adjuvant CT given during and after RT did not significantly improve the 5-year OS compared with radiotherapy alone. Failure-free survival in all stage USC was 58% with chemoradiotherapy versus 48% with radiotherapy (P = 0.11). Interestingly, among all women with stage III endometrial cancer, failurefree survival was significantly improved by 11% in women treated with both chemoradiotherapy; however, OS was not affected. 16 Furthermore, the preliminary data from GOG 258 reported on PFS after treatment with cisplatin with volumedirected radiation followed by 4 cycles of carboplatin and paclitaxel compared with 6 cycles of carboplatin and paclitaxel alone in patients with either advanced endometrioid endometrial cancer or early-stage USC or clear cell cancer. 17 Uterine serous carcinoma comprised 17% of cancers in each arm. Whereas cisplatin-RT reduced the incidence of local recurrences, distant recurrences were more common compared with the CT-only arm. The combined modality regimen did not FIGURE 3. Kaplan-Meier OS curve for stage I patients with and without LVSI in USC patients who were prescribed radiation ''sandwiched'' between 3 cycles of paclitaxel/carboplatin CT before and after RT. Although our trial encompasses a large number of women with USC, the lack of a comparison arm in our trial makes it difficult to directly compare with the subset of USC subjects in prior phase 3 trials powered to assess survival. Also, those prior trials included all histologies, whereas this study assessed arguably one of the highest-risk histologies, USC. Because USC represents the minority of patients in these studies, it remains challenging to extrapolate management recommendations for women with USC, specifically because the definition of USC is less stringent than ours. Therefore, multimodal treatment remains the standard of care for patients with early-and advanced-stage USC. Despite the prospective nature of our study, we recognize that there are limitations; this is a single-institution experience with minor differences in the carboplatin dosing during the initial pilot phase of the trial. However, with optimization during the pilot phase, the final prescribed dose regimen remained consistent. While our report represents the largest prospective study among women with USC, the relatively low number of advanced-stage patients enrolled continues to be a limitation of the data. In addition, further phase 3 trials would be necessary to elucidate the role of the ''sandwich'' approach in patients with USC. However, USC is rare, and such a trial would likely require a significant number of subjects. Furthermore, our study was conducted prior to the publication of the 2014 American Society for Radiation Oncology guidelines on the role of postoperative RT for endometrial cancer, which highlights use of concomitant brachytherapy with EBRT only in patients with significant risk of vaginal recurrence. 18 Given these new guidelines, patients would only receive either EBRT or brachytherapy based on risk factors. Grouping all patients with stages IYIV disease to receive the same treatment further limits the study, given that current guidelines stratify patients to generally receive brachytherapy or EBRT alone.
The strengths of our study is the large number of participants and the prospective nature of this report in women with pure USC. Also, the high number of patients with advancedstage, completely resected disease and no grossly visible disease. The patients represented in this single-institution study is ethnically and racially diverse in Bronx, NY. Furthermore, this study represents a large number of patients who have had complete surgical staging for USC, and 74% (103/140) of patients underwent omentectomy or an omental biopsy as part of the surgical staging procedure.
In summary, our long-term study demonstrates that ''sandwich'' therapy is a well-tolerated treatment approach with acceptable toxicities and reasonable efficacy in patients with completely resected stage IYIV USC. The increased risk of death in stage I patients with LVSI suggests that LVSI is an independent predictor of outcome and further highlighted the importance of multimodal treatment in this group of patients. Finally, contrary to other reports, our study does not demonstrate racial disparity in OS. This data emphasize the need to increase recruitment of racially diverse patients into clinical trials. 19, 20 Further studies are needed to establish the optimal sequencing of adjuvant treatment in patients with USC, which would require a multi-institutional approach given the rarity of the disease.
